Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRTS Stock Forecast 2026-2027
$2.96
Current Price
$48.73M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SRTS Price Targets
+119.6%
To High Target of $6.50
+102.7%
To Median Target of $6.00
+52.0%
To Low Target of $4.50
SRTS Price Momentum
-3.6%
1 Week Change
+9.6%
1 Month Change
-35.5%
1 Year Change
-25.6%
Year-to-Date Change
-50.0%
From 52W High of $5.92
+11.3%
From 52W Low of $2.66
📊 TOP ANALYST CALLS
Did SRTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sensus Healthcare is one of their latest high-conviction picks.
Latest SRTS Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, SRTS has a bullish consensus with a median price target of $6.00 (ranging from $4.50 to $6.50). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $2.96, the median forecast implies a 102.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRTS Analyst Ratings
4
Buy
0
Hold
0
Sell
SRTS Price Target Range
Low
$4.50
Average
$6.00
High
$6.50
Current: $2.96
Latest SRTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 17, 2026 | Maxim Group | Buy | Maintains | $N/A | |
| Aug 12, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Lake Street | Buy | Maintains | $N/A | |
| May 19, 2025 | Maxim Group | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 11, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Feb 10, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 18, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 15, 2024 | Maxim Group | Buy | Maintains | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 13, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 10, 2024 | Maxim Group | Buy | Maintains | $N/A | |
| Nov 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 4, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 4, 2023 | Alliance Global Partners | Buy | Maintains | $N/A | |
| Feb 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 10, 2023 | Alliance Global Partners | Buy | Maintains | $N/A | |
| Nov 4, 2022 | Alliance Global Partners | Buy | Maintains | $N/A | |
| May 6, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Sensus Healthcare Inc. (SRTS) Competitors
The following stocks are similar to Sensus Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SRTS
Sensus Healthcare
mkt cap
50.54M
Sensus Healthcare Inc. (SRTS) Financial Data
Sensus Healthcare Inc. has a market capitalization of $48.73M with a P/E ratio of 49.5x. The company generates $22.53M in trailing twelve-month revenue with a -34.5% profit margin.
Revenue growth is -59.3% quarter-over-quarter, while maintaining an operating margin of -128.4% and return on equity of -15.8%.
Valuation Metrics
Market Cap
$48.73M
Enterprise Value
$32.29M
P/E Ratio
49.5x
PEG Ratio
-183.0x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-59.3%
Gross Margin
+29.2%
Operating Margin
-128.4%
Net Margin
-34.5%
EPS Growth
-59.3%
Financial Health
Cash/Price Ratio
+37.6%
Current Ratio
7.3x
Debt/Equity
0.9x
ROE
-15.8%
ROA
-13.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sensus Healthcare Inc. (SRTS) Business Model
About Sensus Healthcare Inc.
What They Do
Develops non-invasive medical technology for skin treatments.
Business Model
Sensus Healthcare generates revenue by selling mobile superficial radiation therapy (SRT) systems, particularly the SRT-100, to healthcare professionals and facilities. These systems offer a non-surgical alternative for treating conditions like non-melanoma skin cancers and keloids, allowing the company to capitalize on the growing demand for patient-friendly medical solutions.
Additional Information
Founded in the early 2000s, Sensus Healthcare is primarily focused on the U.S. market but is actively expanding internationally. The company's technology emphasizes precision and minimal damage to healthy tissues, which not only improves patient outcomes but also potentially lowers overall healthcare costs.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
60
CEO
Mr. Joseph C. Sardano
Country
United States
IPO Year
2016
Website
sensushealthcare.comSensus Healthcare Inc. (SRTS) Latest News & Analysis
Latest News
Sensus Healthcare Q1 Earnings Call Highlights
2 months ago
Quick Summary
Sensus Healthcare (NASDAQ: SRTS) reported a revenue decline in Q1 2026 due to no sales from its largest customer, despite new CPT codes for superficial radiotherapy being implemented.
Why It Matters
Sensus Healthcare's revenue decline amid new CPT codes signals potential instability, raising concerns over future sales and reliance on key customers, impacting investor confidence.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare, Inc. (SRTS) held its Q1 2026 earnings call, providing insights into its financial performance and strategic initiatives during the quarter.
Why It Matters
The Q1 2026 earnings call for Sensus Healthcare provides insights into the company's financial performance and future outlook, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare reported Q1 2026 revenue of $3.4 million, down from $8.3 million in Q1 2025. The decrease was influenced by reduced sales to its largest customer.
Why It Matters
Declining revenue from $8.3 million to $3.4 million raises concerns about Sensus Healthcare's growth and customer reliance, potentially impacting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
2 months ago
Quick Summary
Sensus Healthcare and SkinCure Oncology have resolved their dispute and are focusing on patient care and clinical excellence, following a lawsuit filed in March 2026.
Why It Matters
The resolution of the dispute with SkinCure Oncology removes legal uncertainties, potentially enhancing Sensus Healthcare's operational stability and investor confidence in future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will report Q1 2026 financial results on May 7, 2026, at 4:30 PM ET, followed by a conference call for updates and Q&A.
Why It Matters
Sensus Healthcare's upcoming financial report and conference call may impact stock performance, providing insights into growth prospects and operational effectiveness, influencing investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare, Inc. has filed a lawsuit against SkinCure Oncology, LLC for breach of contract regarding unpaid amounts owed for services.
Why It Matters
The lawsuit against SkinCure could impact Sensus Healthcare's financial stability and cash flow, potentially affecting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SRTS Stock
What is Sensus Healthcare Inc.'s (SRTS) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Sensus Healthcare Inc. (SRTS) has a median price target of $6.00. The highest price target is $6.50 and the lowest is $4.50.
Is SRTS stock a good investment in 2027?
According to current analyst ratings, SRTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRTS stock?
Wall Street analysts predict SRTS stock could reach $6.00 in the next 12 months. This represents a 102.7% increase from the current price of $2.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sensus Healthcare Inc.'s business model?
Sensus Healthcare generates revenue by selling mobile superficial radiation therapy (SRT) systems, particularly the SRT-100, to healthcare professionals and facilities. These systems offer a non-surgical alternative for treating conditions like non-melanoma skin cancers and keloids, allowing the company to capitalize on the growing demand for patient-friendly medical solutions.
What is the highest forecasted price for SRTS Sensus Healthcare Inc.?
The highest price target for SRTS is $6.50 from at , which represents a 119.6% increase from the current price of $2.96.
What is the lowest forecasted price for SRTS Sensus Healthcare Inc.?
The lowest price target for SRTS is $4.50 from at , which represents a 52.0% increase from the current price of $2.96.
What is the overall SRTS consensus from analysts for Sensus Healthcare Inc.?
The overall analyst consensus for SRTS is bullish. Out of 1 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are SRTS stock price projections?
Stock price projections, including those for Sensus Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 12:20 PM UTC